--- title: "NASH and Specialty Biotech in 13Fs: MDGL, ASND, ARGX, KRYS" type: learn slug: nash-specialty-biotech-13f-mdgl-asnd-argx-krys-reading-guide canonical_url: https://13finsight.com/learn/nash-specialty-biotech-13f-mdgl-asnd-argx-krys-reading-guide published_at: 2026-05-15T06:00:55.624Z updated_at: 2026-05-15T06:00:59.062Z author: Sarah Mitchell author_title: Education Editor author_url: https://13finsight.com/authors/sarah-mitchell word_count: 737 locale: en source: 13F Insight --- # NASH and Specialty Biotech in 13Fs: MDGL, ASND, ARGX, KRYS > Paulson holds Madrigal at 30% of portfolio. Avoro holds MDGL plus ASND, ARGX, KRYS at 12-10% each. NASH, rare-disease, and protein-degradation specialty biotech show up across multiple concentrated 13Fs. Here's how to read them. Specialty biotech — companies focused on rare diseases, novel therapeutic mechanisms, and late-stage clinical programs with binary catalysts — appears in a small but important set of US 13F filings at extreme concentrations. Paulson & Co. holds Madrigal Pharmaceuticals (MDGL) at 30.48% portfolio. Avoro Capital Advisors holds MDGL at 10.35% plus Ascendis Pharma (ASND) at 10.72%, Argenx (ARGX) at 8.18%, and Krystal Biotech (KRYS) at 7.00%. Smaller biotech-specialist funds and crossover venture investors show similar concentration patterns. Reading these positions requires understanding the specialty-biotech category — what these companies do, why active managers concentrate in them, and what to watch for catalysts.What specialty biotech actually isThe 'specialty biotech' category typically includes:Rare-disease specialists. Companies developing therapies for diseases affecting fewer than 200,000 US patients. Regulatory incentives (orphan drug designation, pediatric vouchers) plus pricing-power dynamics make these commercially viable despite small patient populations. Examples: BioMarin, Vertex (which has expanded beyond), Ascendis Pharma, Krystal Biotech, Ionis Pharmaceuticals.Novel mechanism platforms. Companies whose drug-discovery platform represents a distinct technological approach. Examples: Argenx (FcRn antagonism), Kymera Therapeutics (protein degradation), Arrowhead Pharmaceuticals (RNAi), Avidity Biosciences (antibody-oligonucleotide conjugates), Structure Therapeutics (oral GLP-1).First-in-class commercial assets. Companies that have achieved FDA approval for the first therapy in a disease category. Examples: Madrigal Pharmaceuticals (first oral NASH therapy), Ascendis Pharma (Skytrofa for achondroplasia, Yorvipath for hypoparathyroidism).Late-stage clinical programs with binary catalysts. Companies with Phase 3 readouts approaching that determine commercial viability.Why specialty biotech produces concentrated 13F betsThree structural drivers:Binary catalysts produce asymmetric returns. A Phase 3 readout or FDA approval can double the stock; a failure can halve it. Position sizing reflects conviction in the underlying scientific and commercial thesis.Small market caps allow meaningful position sizing. Many specialty biotech names are sub-$10 billion market cap. A $1 billion position represents 10%+ ownership — too big for diversified active managers but appropriate for specialist funds with smaller AUM.Specialist research is required. Biotech investing requires medical-and-scientific research depth that most diversified active managers don't have in-house. Specialist firms (Avoro, Baker Bros, RTW Investments, Perceptive Advisors, Deep Track Capital, Bain Capital Life Sciences) compete in this category.The major specialty-biotech 13F filersAvoro Capital Advisors — $10.17B AUM, top 10 entirely biotech (UTHR, ASND, MDGL, ARGX, KRYS, ARWR, KYMR, GPCR, RNA, CNTA). Cleanest pure-play biotech specialist.Baker Bros. Advisors — Long-running biotech-only investor with concentrated positions.Perceptive Advisors — Biotech specialist with crossover venture + public-equity strategies.RTW Investments — Multi-fund biotech specialist.Deep Track Capital — Biotech specialist.Bain Capital Life Sciences — Multi-strategy biotech-and-life-sciences investor.Paulson & Co. — Not biotech-only but holds Madrigal at 30.48% portfolio as the largest single position.How to read specialty biotech concentrationThree rules:Rule 1: Read the position weight against the catalyst calendarConcentrated specialty-biotech positions usually align with specific clinical or commercial catalysts. Madrigal's commercial uptake post-FDA approval (March 2024) drove Paulson's 30% concentration. Avoro's combined NASH (MDGL) + rare disease (ASND, KRYS) + autoimmune (ARGX) + protein-degradation (KYMR) + RNAi (ARWR) positions each reflect specific Phase 3 readouts or commercial-launch trajectories.Rule 2: Watch for catalyst-driven exitsSpecialty-biotech positions can compress quickly post-catalyst:Positive Phase 3 readout: Position typically holds or expands modestly; partial profit-taking is common.Negative Phase 3 readout: Position drops sharply; specialist managers often trim aggressively to redeploy capital into other names.Acquisition rumor: Specialists sometimes accumulate ahead of expected M&A; the position trims at takeout premium.Rule 3: Cross-check against insider activity and biotech-specialist consensusSpecialty-biotech investments work best when multiple specialist managers converge on the same names. When Avoro, RTW, Perceptive, and Baker Bros all hold a name at top-10 concentration, the cross-fund consensus is structural. When only one specialist holds it, the conviction is idiosyncratic and the binary risk is higher.The current consensus namesMadrigal Pharmaceuticals (MDGL): NASH commercial-launch story. Paulson + Avoro + multiple other specialist managers concentrate at meaningful weights.Ascendis Pharma (ASND): Rare-disease (achondroplasia, hypoparathyroidism) franchise with TransCon platform extension.Argenx (ARGX): Vyvgart franchise in autoimmune neuromuscular disease.Krystal Biotech (KRYS): Vyjuvek topical gene therapy.These four names appear together in multiple specialist 13Fs at top-10 concentrations. The cross-fund consensus is the structural underpinning of the institutional view on the specialty biotech category.What to trackQuarterly clinical and commercial readouts. Each top-tier specialty biotech has multiple readouts annually. Tracking them produces the underlying catalyst pipeline.Specialist fund flow. Position changes at Avoro, RTW, Perceptive, Baker Bros, Bain Life Sciences signal sector-rotation views.Big-pharma M&A. Specialty-biotech leaders are frequent takeout candidates. Watch the M&A calendar.For real-time tracking of specialty-biotech 13F activity, see the institutional signals feed. For related reading techniques on concentrated active manager 13Fs, see our explainer hub. ## FAQ ### What is specialty biotech in 13F filings? Specialty biotech is a category of US-listed biopharmaceutical companies focused on rare diseases, novel therapeutic mechanisms, first-in-class commercial assets, and late-stage clinical programs with binary catalysts. Examples include Madrigal Pharmaceuticals (first oral NASH therapy), Ascendis Pharma (rare-disease franchise), Argenx (autoimmune neuromuscular), Krystal Biotech (topical gene therapy), Kymera Therapeutics. These names appear at concentrated weights in specialist filings. ### Why does Paulson hold 30% of his portfolio in Madrigal? Madrigal Pharmaceuticals received FDA approval for resmetirom (Rezdiffra) in March 2024 as the first oral therapy for NASH. The addressable US NASH patient population is estimated at 1.5-2 million biopsy-eligible patients with peak revenue potential of $5-10 billion. Limited Phase 3 competition plus single-asset commercial biotech acquisition optionality makes MDGL a textbook concentrated special-situations bet at $994 million / 30.48% portfolio. ### How concentrated are pure biotech-specialist 13Fs? Avoro Capital Advisors holds 77.7% of its $10.17 billion 13F in the top 10 specialty biotech names — UTHR, ASND, MDGL, ARGX, KRYS, ARWR, KYMR, GPCR, RNA, CNTA. Each position is at 4-12% portfolio weight. Specialist funds run this concentration because small market caps allow meaningful position sizing and specialist medical-and-scientific research depth is required. ### Should I follow specialty biotech 13F positions as trade signals? With caveats. Specialty biotech is high-information when multiple specialist managers converge on the same names (Avoro + RTW + Perceptive + Baker Bros all holding ASND at top-10 concentration signals structural consensus). Single-specialist positions carry idiosyncratic binary risk — positive Phase 3 readouts produce 50-100%+ moves, negative readouts produce 30-50% drops. Position sizing should reflect the binary-catalyst risk-reward. ### Which specialty biotech firms are major 13F filers? Major specialty-biotech-focused 13F filers include Avoro Capital Advisors (~$10B, top 10 pure biotech), Baker Bros. Advisors (concentrated long-running specialist), Perceptive Advisors (crossover venture + public), RTW Investments (multi-fund), Deep Track Capital (specialist), and Bain Capital Life Sciences (multi-strategy). Generalist filers like Paulson & Co. also concentrate in specialty biotech when specific catalysts align with their special-situations philosophy. ### What is the typical specialty biotech catalyst calendar? Specialty biotech catalysts typically include Phase 3 clinical-trial readouts (binary success/failure events), FDA approval decisions (PDUFA dates), label-expansion decisions for already-approved drugs, commercial-launch milestones (initial Rx prescriptions, payer coverage), and big-pharma acquisition rumors or announcements. Each catalyst can move the stock 20-100% in either direction, which is why position sizing in 13F filings reflects conviction in the catalyst outcome. --- Source: 13F Insight — https://13finsight.com/learn/nash-specialty-biotech-13f-mdgl-asnd-argx-krys-reading-guide Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell Last updated: 2026-05-15T06:00:59.062Z